Literature DB >> 19099507

Vincristine-induced overexpression of P-glycoprotein in L1210 cells is associated with remodeling of cell surface saccharides.

Zdenka Sulová1, Danica Mislovicová, Lenka Gibalová, Zuzana Vajcnerová, Eva Poláková, Branislav Uhrík, Lucia Tylková, Annámaria Kovarova, Ján Sedlák, Albert Breier.   

Abstract

Multidrug resistance of murine leukemic cell line L1210/VCR (R), obtained by adaptation of parental L1210 cells (S) on vincristine, is associated with overexpression of P glycoprotein (P-gp, the ATP-dependent drug efflux pump). Previously, we found that cytochemical staining of negatively charged cell surface binding sites (probably sialic acid) by ruthenium red (RR) revealed a compact layer of RR bound to the external coat of S cells. This is in contrast to R cells and L1210/VCR cells cultured in the presence of vincristine during the last cultivation prior to the experiment (V cells), where the RR layer was either reduced or absent. In the current paper, we observed differences in the interactions of S, R and V cells with Concanavalin A (ConA) and tomato lectin (lycopersicum esculentum agglutinin, LEA). ConA bound and induced cell damage more effectively in S cells than in R or V cells. Both of these effects could be prevented by methyl-manopyranose, but not by N-acetylglucosamine. In contrast, LEA lectin preferentially bound to R and V cells. While LEA agglutinated cells more effectively than ConA, it did not cause cell damage comparable to ConA. Binding of LEA to the cell surface could be prevented by chitooligosaccharides. Both LEA and ConA failed to identify P-gp in lectin blots. Thus, changes in ConA and LEA interactions are not caused by massive expression of P-gp in the plasma membrane and the consequent exposure of the inner saccharides to the external side of the plasma membrane.Taken together, the above facts suggest that S cells differ from R and V cells in the composition of cell surface glycosides not directly linked to P-gp.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19099507     DOI: 10.1021/pr8007094

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  6 in total

Review 1.  Electrochemistry of nonconjugated proteins and glycoproteins. Toward sensors for biomedicine and glycomics.

Authors:  Emil Paleček; Jan Tkáč; Martin Bartošík; Tomáš Bertók; Veronika Ostatná; Jan Paleček
Journal:  Chem Rev       Date:  2015-02-09       Impact factor: 60.622

2.  Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 cells.

Authors:  Mário Sereš; Dana Cholujová; Tatiana Bubenčíkova; Albert Breier; Zdenka Sulová
Journal:  Int J Mol Sci       Date:  2011-11-10       Impact factor: 5.923

Review 3.  The Roles of microRNAs in Cancer Multidrug Resistance.

Authors:  Lucia Pavlíková; Mário Šereš; Albert Breier; Zdena Sulová
Journal:  Cancers (Basel)       Date:  2022-02-21       Impact factor: 6.639

4.  Detection of glycomic alterations induced by overexpression of p-glycoprotein on the surfaces of L1210 cells using sialic acid binding lectins.

Authors:  Tatiana Bubencíkova; Dana Cholujová; Lucia Messingerová; Danica Mislovicova; Mario Seres; Albert Breier; Zdena Sulova
Journal:  Int J Mol Sci       Date:  2012-11-16       Impact factor: 5.923

5.  L1210 Cells Overexpressing ABCB1 Drug Transporters Are Resistant to Inhibitors of the N- and O-glycosylation of Proteins.

Authors:  Lucia Pavlikova; Mario Seres; Milan Hano; Viera Bohacova; Ivana Sevcikova; Tomas Kyca; Albert Breier; Zdena Sulova
Journal:  Molecules       Date:  2017-07-03       Impact factor: 4.411

6.  Overexpression of GRP78/BiP in P-Glycoprotein-Positive L1210 Cells is Responsible for Altered Response of Cells to Tunicamycin as a Stressor of the Endoplasmic Reticulum.

Authors:  Mário Šereš; Lucia Pavlíková; Viera Boháčová; Tomáš Kyca; Ivana Borovská; Boris Lakatoš; Albert Breier; Zdena Sulová
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.